Cytokinetics' Heart Drug Gains FDA Approval, Boosting Its Market Edge
Originally Published 23 days ago — by statnews.com

Cytokinetics received FDA approval for its first drug, Myqorzo, to treat obstructive hypertrophic cardiomyopathy, ending a 27-year R&D drought for the company. The drug will compete with a similar medication from Bristol Myers Squibb and is expected to launch in late January.
